Abstract

Hepatoprotective Effect of the N-Alkylated Isobornylamine against CCl4-Induced Chronic Liver Damage in Mice †

Darya Pon’kina *, Sergey Kuranov, Nataliya Zhukova, Yulia Meshkova, Mikhail Khvostov, Olga Luzina, Tatyana Tolstikova and Nariman Salakhutdinov

N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, 630090 Novosibirsk, Russia
* Correspondence: darya.kuznetsova4@gmail.com
† Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/ .

Abstract: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by impaired lipid and carbohydrate metabolism, and is characterized by fatty degeneration, necrosis, inflammation, and fibrosis of hepatocytes. There are currently no approved drugs for the treatment of NAFLD, so their search remains an urgent task for present pharmacology. Previously, N-alkylated isobornylamine (compound 1), a GPR40 agonist, at a dose of 30 mg/kg was shown to resolve fatty liver degeneration in C57Bl/6 Ay mice and improve glucose tolerance. As a result, we continued to study the hepatoprotective effect of compound 1 on CCl4-induced chronic hepatotoxicity model in CD-1 mice. Compound 1 was administered per os at doses of 60, 90, 120 and 150 mg/kg daily for 3 weeks, as well as the reference drug silymarin at a dose of 100 mg/kg. At the end of the experiment, a biochemical blood assay was carried out, which showed that compound 1 dose-dependently reduces ALT, AST and ALKP. According to the results of a histological and morphometry liver examination, compound 1 was found to reduce the severity of degenerative-necrotic changes in hepatocytes. More pronounced improvements in doses of 120 and 150 mg/kg were noted. Thus, isobornylamine derivative exhibits a hepatoprotective effect not only in metabolic liver injury, but also in CCl4-induced chronic liver damage.

Keywords: CCl4-induced liver damage; hepatoprotection drug; type 2 diabetes; nonalcoholic fatty liver disease; GPR40; FFAR1


Author Contributions: Chemistry investigation, S.K.; under the supervision of O.L.; in vivo investigation, D.P., N.Z. and Y.M.; under the supervision of M.K. and T.T.; project administration, S.K.; supervision, N.S. and O.L.; writing—original draft, D.P., S.K., M.K. and N.Z.; writing—review and editing, D.P. and M.K. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the Russian Science Foundation grant No. 21-73-00246.

Institutional Review Board Statement: The animal study protocol was approved by the Ethic Committee of the N.N. Vorozhtsov Institute of Organic Chemistry SB RAS (protocol No. P-01-04-2022-14).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.